Literature DB >> 9634331

Should preventive antiretroviral treatment be offered following sexual exposure to HIV? Not yet!

B Evans1, J Darbyshire, J Cartledge.   

Abstract

Mesh:

Substances:

Year:  1998        PMID: 9634331      PMCID: PMC1758097          DOI: 10.1136/sti.74.2.146

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


× No keyword cloud information.
  5 in total

1.  AIDS and HIV infection acquired through sexual intercourse between men.

Authors:  N D Macdonald
Journal:  Commun Dis Rep CDR Rev       Date:  1997-08-22

2.  Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.

Authors:  S D Pinkerton; D R Holtgrave; H J Pinkerton
Journal:  Arch Intern Med       Date:  1997-09-22

3.  AIDS and severe HIV disease: combined predictions for the United Kingdom to 1999.

Authors:  G Allardice; G Hughes
Journal:  Commun Dis Rep CDR Rev       Date:  1996-12-06

4.  Health care workers and HIV: surveillance of occupationally acquired infection in the United Kingdom.

Authors:  J Heptonstall; O N Gill; K Porter; M B Black; V L Gilbart
Journal:  Commun Dis Rep CDR Rev       Date:  1993-10-08

5.  A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group.

Authors:  D M Cardo; D H Culver; C A Ciesielski; P U Srivastava; R Marcus; D Abiteboul; J Heptonstall; G Ippolito; F Lot; P S McKibben; D M Bell
Journal:  N Engl J Med       Date:  1997-11-20       Impact factor: 91.245

  5 in total
  2 in total

Review 1.  Management of occupational and nonoccupational postexposure HIV prophylaxis.

Authors:  Mitchell H Katz; Julie Louise Gerberding
Journal:  Curr HIV/AIDS Rep       Date:  2004-12       Impact factor: 5.495

2.  Management of Occupational and Nonoccupational Postexposure HIV Prophylaxis.

Authors:  Mitchell H. Katz; Julie Louise Gerberding
Journal:  Curr Infect Dis Rep       Date:  2002-12       Impact factor: 3.663

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.